Enhanced immune responses and effectiveness of refined outer membrane protein vaccines against Vibrio harveyi in orange-spotted grouper (Epinephelus coioides)

© 2018 John Wiley & Sons Ltd.

Bibliographische Detailangaben
Veröffentlicht in:Journal of fish diseases. - 1998. - 41(2018), 9 vom: 08. Sept., Seite 1349-1358
1. Verfasser: Nguyen, Hai Trong (VerfasserIn)
Weitere Verfasser: Nguyen, Thuy Thi Thu, Chen, Yan-Chun, Vu-Khac, Hung, Wang, Pei-Chi, Chen, Shih-Chu
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Journal of fish diseases
Schlagworte:Journal Article Vibrio harveyi ISA 763 A VG fusion protein vaccine vibriosis Adjuvants, Immunologic Antibodies, Bacterial Bacterial Outer Membrane Proteins Bacterial Vaccines mehr... Fish Proteins Interleukin-1beta Interleukin-8 Recombinant Proteins
Beschreibung
Zusammenfassung:© 2018 John Wiley & Sons Ltd.
Vibriosis is a severe infection occurring in many commercially important marine fish species. In this study, vaccines containing Vibrio harveyi recombinant outer membrane protein K (rOmpK), outer membrane protein U (rOmpU) and rOmpK-OmpU fusion protein in addition to the metabolizable MontanideTM ISA 763 A VG adjuvant were developed and evaluated in the orange-spotted grouper. The results indicate that recombinant V. harveyi protein-based vaccines resulted in a remarkably higher expression of IL-1β and IL-8 at 24 hr, and greater antibody production, as early as 2 weeks postimmunization. Notably, enhanced immune responses and significant protective efficacy against V. harveyi infections were observed in the fusion protein vaccine-injected fishes with relative per cent survival value of 81.8%. Additionally, the rOmpK-OmpU antisera presented a high bactericidal effect on not only V. harveyi, but also Vibrio parahaermolyticus and Vibrio alginolyticus. Our results demonstrated that the fusion protein rOmpK-OmpU was an effective vaccine candidate that exhibited potentially great versatility for controlling vibrio infections
Beschreibung:Date Completed 30.01.2019
Date Revised 30.09.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1365-2761
DOI:10.1111/jfd.12828